Epidemiology of Acute Hepatitis B in the United States from Population-Based Surveillance, 2006-2011

Clinical Infectious Diseases

Volumn 61, Issue 4, 2015, Pages 584-592

  Iqbal, Kashif ^a   Klevens, R Monina ^a   Kainer, Marion A ^b   Baumgartner, Jennifer ^c   Gerard, Kristin ^d   Poissant, Tasha ^e   Sweet, Kristin ^f   Vonderwahl, Candace ^g   Knickerbocker, Tracey ^h   Khudyakov, Yury ^a   Xia, Guo Liang ^a   Roberts, Henry ^a   Teshale, Eyasu ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b TENNESSEE DEPARTMENT OF HEALTH   (United States)

^c New York Department of Health and Mental Hygiene   (United States)

^d Connecticut Department of Public Health ^*  (United States)

^e OREGON HEALTH AUTHORITY   (United States)

^f MINNESOTA DEPARTMENT OF HEALTH   (United States)

^g Colorado Department of Public Health and Environment ^*  (United States)

^h State of New York Dept of Health   (United States)

Author keywords

drug use; genotype; hepatitis B; incidence; surveillance

Indexed keywords

HEPATITIS VACCINE;

ACUTE HEPATITIS B; ADOLESCENT; ADULT; AGED; CAUCASIAN; CHILD; DISEASE CONTROL; DISEASE SURVEILLANCE; DRUG USE; FEMALE; HEALTH SURVEY; HEPATITIS B VIRUS GENOTYPE A; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK FACTOR; UNITED STATES; VACCINATION; CLASSIFICATION; DEMOGRAPHY; EPIDEMIOLOGICAL MONITORING; ETHNIC GROUP; GENETICS; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; ISOLATION AND PURIFICATION; MIDDLE AGED; QUESTIONNAIRE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; DEMOGRAPHY; EPIDEMIOLOGICAL MONITORING; ETHNIC GROUPS; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RISK FACTORS; SURVEYS AND QUESTIONNAIRES; UNITED STATES; YOUNG ADULT;

EID: 84938594283     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ332     Document Type: Review

References (36)

1. Wasley A, Kruszon D, Kuhnert-MoranW, et al. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis 2010; 202:192-201.
2. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156:271-8.
3. Centers for Disease Control and Prevention. Viral hepatitis surveillance-United States. 2010. Available at: http://www.cdc.gov/hepatitis/Statistics/2011Surveillance/index.htm. Accessed 6 May 2015.
4. Mast EE, Margolis HS, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005; 54(RR-16):1-31.
5. Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006; 55(RR-16):1-33; quiz CE1-4.
6. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1991; 40(RR-13):1-25.
7. Immunization of adolescents. Recommendations of the Advisory Committee on Immunization Practices, the American Academy of Pediatrics, the American Academy of Family Physicians, and the American Medical Association. MMWR Recomm Rep 1996; 45(RR-13):1-16.
8. Centers for Disease Control and Prevention. National and state vaccination coverage among children aged 19-35 months-United States, 2010. MMWR Morb Mortal Wkly Rep 2011; 60:1157-63.
9. Centers for Disease Control and Prevention. National and state vaccination coverage among adolescents aged 13 through 17 years-United States, 2010. MMWR Morb Mortal Wkly Rep 2011; 60:1117-23.
10. Goldstein ST, Alter MJ,Williams IT, et al. Incidence and risk factors for acute hepatitis B in the United States, 1982-1998: implications for vaccination programs. J Infect Dis 2002; 185:713-9.
11. Emerging Infections Program (EIP). Available at: http://www.cdc.gov/ncpdcid/deiss/about-eip.html. Accessed 6 May 2015.
12. US Census Bureau. Methodology for the intercensal population and housing unit estimates: 2000 to 2010. 2012. Available at: http://www.census.gov/popest/methodology/2000-2010-Intercensal-Estimates- Methodology.pdf. Accessed 6 May 2015.
13. Forbi JC, Vaughan G, Purdy MA, et al. Epidemic history and evolutionary dynamics of hepatitis B virus infection in two remote communities in rural Nigeria. PLoS One 2010; 5:e11615.
14. Havens JR, Lofwall MR, Frost SD, Oser CB, Leukefeld CG, Crosby RA. Individual and network factors associated with prevalent hepatitis C infection among rural Appalachian injection drug users. Am J Public Health 2013; 103:e44-52.
15. Christian WJ, Hopenhayn C, Christian A, McIntosh D, Koch A. Viral hepatitis and injection drug use in Appalachian Kentucky: a survey of rural health department clients. Public Health Rep 2010; 125:121-8.
16. Young AM, Crosby RA, Oser CB, Leukefeld CG, Stephens DB, Havens JR. Hepatitis C viremia and genotype distribution among a sample of nonmedical prescription drug users exposed to HCV in rural Appalachia. J Med Virol 2012; 84:1376-87.
17. Bruneau J, Roy E, Arruda N, Zang G, Jutras-Aswad D. The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users. Addiction 2012; 107:1318-27.
18. Suryaprasad A, White J, Xu F, et al. Emerging epidemic of hepatitis C virus infections among young non-urban persons who inject drugs in the United States, 2006-2012. Clin Infect Dis 2014; 59: 1411-9.
19. US Department of Health and Human Services. Technical consultation: hepatitis C virus infection in young persons who inject drugs. 2013. Available at: https://www.aids.gov/pdf/hcv-and-young-pwid-consultationreport. pdf. Accessed 6 May 2015.
20. Margolis HS, Alter MJ, Hadler SC. Hepatitis B: evolving epidemiology and implications for control. Semin Liver Dis 1991; 11:84-92.
21. Petterson SM, Liaw WR, Phillips RL Jr, Rabin DL, Meyers DS, Bazemore AW. Projecting US primary care physician workforce needs: 2010-2025. Ann Fam Med 2012; 10:503-9.
22. Wise ME, Marquez P, Sharapov U, et al. Outbreak of acute hepatitis B virus infections associated with podiatric care at a psychiatric long-term care facility. Am J Infect Control 2012; 40:16-21.
23. Greeley RD, Semple S, Thompson ND, et al. Hepatitis B outbreak associated with a hematology-oncology office practice in New Jersey, 2009. Am J Infect Control 2011; 39:663-70.
24. Thompson ND, Schaefer MK. Never events: hepatitis B outbreaks and patient notifications resulting from unsafe practices during assisted monitoring of blood glucose, 2009-2010. J Diabetes Sci Technol 2011; 5:1396-402.
25. Thompson ND, Perz JF, Moorman AC, Holmberg SD. Nonhospital health care-associated hepatitis B and C virus transmission: United States, 1998-2008. Ann Intern Med 2009; 150:33-9.
26. Bender TJ, Wise ME, Utah O. Outbreak of hepatitis B virus infections associated with assisted monitoring of blood glucose in an assisted living facility-Virginia, 2010. PLoS One 2012; 7:e50012.
27. Thompson ND, Perz JF. Eliminating the blood: ongoing outbreaks of hepatitis B virus infection and the need for innovative glucose monitoring technologies. J Diabetes Sci Technol 2009; 3:283-8.
28. Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention. Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60(RR-7):1-45.
29. Teshale EH, Ramachandran S, Xia GL, et al. Genotypic distribution of hepatitis B virus (HBV) among acute cases of HBV infection, selected United States counties, 1999-2005. Clin Infect Dis 2011; 53:751-6.
30. Kao JH. HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon? Liver Int 2014; 34(suppl 1):112-9.
31. Fung SK, Lok AS. Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection? Hepatology 2004; 40:790-2.
32. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50:661-2.
33. Damerow H, Yuen L, Wiegand J, Walker C, Bock CT, Locarnini S, Tillmann HL. Mutation pattern of lamivudine resistance in relation to hepatitis B genotypes: hepatitis B genotypes differ in their lamivudine resistance associated mutation pattern. J Med Virol 2010; 82:1850-8.
34. Matsuura K, Tanaka Y, Hige S, et al. Distribution of hepatitis B virus genotypes among patients with chronic infection in Japan shifting toward an increase of genotype A. J Clin Microbiol 2009; 47:1476-83.
35. Iqbal K, Klevens RM, Jiles R. Comparison of acute viral hepatitis data quality using two methodologies, 2005-2007. Public Health Rep 2012; 127:591-7.
36. Klompas M, Murphy M, Lankiewicz J, et al. Harnessing electronic health records for public health surveillance. Online J Public Health Inform 2011; doi:10.5210/ojphi.v3i3.3794.